Tumor reactivity assessment using clonal expression reveals tumor reactive CD8+ T cell heterogeneity across solid tumors
Introduction: TIL are composed of T cells that recognize tumor antigens (Tumor Reactive T cells, or TRTs) as well as bystander T cells with specificity for other antigens. TRT clonotypes are associated with a unique and tumor-driven exhausted transcriptional state, enabling single-cell RNA sequencing (scRNA-seq)-based predictive models for TRTs using experimentally validated clone labels. Methods: TRT classifier (TRACE) was built using an aggregated dataset of validated tumor reactive clonotypes and associated scRNA-seq data from multiple publications that overcomes the limitations of training on a single dataset, donor, or indication. TRACE does not require dataset manipulation for training or prediction, enabling it to be easily applied to new test datasets as they emerge. Results: T cells in tumors but not in exhausted cells in normal adjacent or non-cancer samples, suggesting specificity towards identifying tumor-antigen experienced T cells. Conclusion: TRACE is a tumor reactivity scoring algorithm released with open model weights that can be applied to tissue or blood single-cell RNAseq datasets. Its application should be of general interest for characterizing the fraction of TRTs in TIL and for establishing correlations with clinical response to immunotherapies.
Authors
- Charles H. Yoon (ORCID: https://orcid.org/0000-0003-1231-3840)
- Dipen Sangurdekar (ORCID: https://orcid.org/0000-0001-9474-0808)
- Ashish Yeri
- Mitali Ghose
- Karrie Wong (ORCID: https://orcid.org/0000-0001-8998-6416)
- Conor Calnan
- Micah J. Benson
- Anne E. Dodson (ORCID: https://orcid.org/0000-0001-7719-0496)
- Sophie Capobianco
- Jack Denebeim
- Meghan Travers
- David Monteiro
- Gustavo J. Martinez
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Q Therapeutics (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-04-16
- DOI
- https://doi.org/10.3389/fimmu.2026.1815974
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00